Cell MedX Corp. (CMXC)
USD 0.43
(0.0%)
USD 0.43
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 287.46 Thousand USD | -68.68% |
| 2023 | 1 Million USD | 62.3% |
| 2022 | 616.78 Thousand USD | 79.47% |
| 2021 | 343.66 Thousand USD | -31.6% |
| 2020 | 502.43 Thousand USD | -1.82% |
| 2019 | 511.75 Thousand USD | 335.69% |
| 2018 | 117.45 Thousand USD | -78.3% |
| 2017 | 541.29 Thousand USD | -43.12% |
| 2016 | 951.71 Thousand USD | 247.6% |
| 2015 | 273.79 Thousand USD | 1293.59% |
| 2014 | 19.64 Thousand USD | 52.93% |
| 2013 | 12.84 Thousand USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.05 Million USD | 5.53% |
| 2024 FY | 287.46 Thousand USD | -71.28% |
| 2024 Q4 | 287.46 Thousand USD | -10.72% |
| 2024 Q3 | 321.99 Thousand USD | -68.83% |
| 2024 Q2 | 1.03 Million USD | -2.2% |
| 2023 Q2 | 765.26 Thousand USD | 12.15% |
| 2023 Q3 | 869.02 Thousand USD | 13.56% |
| 2023 Q1 | 682.34 Thousand USD | 10.63% |
| 2023 FY | 1 Million USD | 62.3% |
| 2023 Q4 | 1 Million USD | 15.19% |
| 2022 Q3 | 561.16 Thousand USD | 18.77% |
| 2022 Q1 | 377.7 Thousand USD | 9.9% |
| 2022 Q2 | 472.48 Thousand USD | 25.09% |
| 2022 FY | 616.78 Thousand USD | 79.47% |
| 2022 Q4 | 616.78 Thousand USD | 9.91% |
| 2021 Q3 | 757.3 Thousand USD | 17.2% |
| 2021 FY | 343.66 Thousand USD | -31.6% |
| 2021 Q4 | 343.66 Thousand USD | -54.62% |
| 2021 Q1 | 591.89 Thousand USD | 17.8% |
| 2021 Q2 | 646.17 Thousand USD | 9.17% |
| 2020 Q2 | 363.82 Thousand USD | 124.07% |
| 2020 FY | 502.43 Thousand USD | -1.82% |
| 2020 Q1 | 162.37 Thousand USD | -68.27% |
| 2020 Q3 | 422.89 Thousand USD | 16.24% |
| 2020 Q4 | 502.43 Thousand USD | 18.81% |
| 2019 Q4 | 511.75 Thousand USD | 7.52% |
| 2019 Q1 | 170.88 Thousand USD | 45.49% |
| 2019 Q2 | 194.37 Thousand USD | 13.74% |
| 2019 FY | 511.75 Thousand USD | 335.69% |
| 2019 Q3 | 475.96 Thousand USD | 144.87% |
| 2018 Q3 | 100.65 Thousand USD | 1.95% |
| 2018 Q1 | 574.37 Thousand USD | 6.11% |
| 2018 FY | 117.45 Thousand USD | -78.3% |
| 2018 Q4 | 117.45 Thousand USD | 16.69% |
| 2018 Q2 | 98.73 Thousand USD | -82.81% |
| 2017 FY | 541.29 Thousand USD | -43.12% |
| 2017 Q1 | 1.12 Million USD | 17.95% |
| 2017 Q2 | 130.12 Thousand USD | -88.41% |
| 2017 Q3 | 282.86 Thousand USD | 117.38% |
| 2017 Q4 | 541.29 Thousand USD | 91.36% |
| 2016 Q1 | 399.16 Thousand USD | 45.79% |
| 2016 FY | 951.71 Thousand USD | 247.6% |
| 2016 Q4 | 951.71 Thousand USD | 41.25% |
| 2016 Q3 | 673.78 Thousand USD | 40.44% |
| 2016 Q2 | 479.75 Thousand USD | 20.19% |
| 2015 Q2 | 125.37 Thousand USD | 1175.64% |
| 2015 Q1 | 9828.00 USD | -49.98% |
| 2015 Q4 | 273.79 Thousand USD | 38.19% |
| 2015 FY | 273.79 Thousand USD | 1293.59% |
| 2015 Q3 | 198.13 Thousand USD | 58.04% |
| 2014 Q4 | 19.64 Thousand USD | 21.68% |
| 2014 Q3 | 16.14 Thousand USD | 25.69% |
| 2014 Q2 | 12.84 Thousand USD | 0.0% |
| 2014 Q1 | 12.84 Thousand USD | 0.0% |
| 2014 FY | 19.64 Thousand USD | 52.93% |
| 2013 Q4 | 12.84 Thousand USD | 0.0% |
| 2013 FY | 12.84 Thousand USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| RetinalGenix Technologies Inc. | 506.53 Thousand USD | 43.248% |